New injectable drug changes fight against HIV | Watch on KHOU 11+
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
emjreviews.com8m
EMA grants accelerated review to Gilead’s PrEP drug
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
The Pharma Letter6h
Analyst predicts Gilead’s lenacapavir could revolutionize HIV prevention
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
Gilead announces European Medicines Agency validation for lenacapavir
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
GlobalData on MSN5d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
News Medical on MSN4d
New HIV therapy lenacapavir shows high efficacy in Ugandan population
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Managed Healthcare Executive5d
FDA Accepts NDA for Gilead's New HIV Prevention Shot
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Science Daily4d
New therapy may effectively control HIV in Uganda
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Bay Area Reporter4d
Twice-yearly PrEP could be available this summer
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Monthly Prescribing Reference5d
Twice-Yearly Lenacapavir Gets Priority Review For HIV PrEP
The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...